New Vistas in Chronic Schizophrenia

References

• Ackner B., Oldham A. J. Insulin treatment of schizophrenia. Lancet 1962; 1: 504–506
   PubMed Web of Science ®Google Scholar
• Alphonsus S., Lichtigfeld F. J. Regional neuronal activity in schizophrenia. South African Medical Journal 1984; 66: 126
   PubMedGoogle Scholar
• Altschule M. D. Effect of a pineal extract on carbohydrate metabolism in schizophrenic patients. Frontiers of pineal physiology, M. D. Altschule. MIT Press, London 1975; 197–203
   Google Scholar
• Antelman S. M., Eichler J., Black C. A., Kocan D. Interchangeability of stress and amphetamines in sensitization. Science 1980; 207: 329–31
   PubMed Web of Science ®Google Scholar
• Bachelard H. S. Brain biochemistry; Second edition. Chapman and Hall, London 1976; 7–11
   Google Scholar
• Barron M. J., Roth R. H. Pharmacology of mesocortical dopamine neurons. Pharmacological Reviews 1983; 35: 53–69
   PubMedGoogle Scholar
• Belmaker R. H., Lerer B., Zohr J. Salbutamol treatment of depression. Typical and atypical anlidepressunr. Clinical practice, E. Costa, G. Racagni. Raven Press, New York 1982; 181–193
   Google Scholar
• Bigelow L. B. Some effects of aqueous pineal extract administration on chronic schizophrenia symptoms. Frontiers of pineal physiology, M. D. Altschule. MIT Press, London 1975; 225–263
   Google Scholar
• Biggio G., Casu M., Corda M. G., DiBelli C., Gessa G. L. Stimulation of dopamine synthesis in caudate nucleus by intrastriatal encephalins and antagonism by naloxine. Science 1978; 200: 552–554
   PubMed Web of Science ®Google Scholar
• Bjerkenstedt L., Edman G., Hagenfeldt L., Sedvall G., Wiesel F. A. Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic and health controls. British Journal of Psychiatry 1985; 147: 276–282
   PubMed Web of Science ®Google Scholar
• Brodie J. D., Christman D. R., Corona J. F., Fowler J. S., Gomez-Mont F., Jaeger J., Michaels P. A., Rotrosen J., Russell J. A., Volkow N. D., Wikler A., Wolf A. P., Wolkin A. Patterns of metabolic activity in the treatment of schizophrenia. Annals of Neurology. Supplement 1984; 15: S166–S169
   Web of Science ®Google Scholar
• Brodie J. D., Wolf A. P., Volkow N., Christman D. R., De Fina P., De Leon M., Farkas T., Ferris S. H., Fowler J. S., Gomez-Mont F., Jaeger J., Russell J. A. G., Stamm R., Yonekura Y. Evaluation of regional glucose metabolism with positron emission tomography in normal and psychiatric populations. Positron emission tomography of the brain, W. D. Heiss, M. E. Phelps. Springer-Verlag, New York 1983; 201–206
   Google Scholar
• Buchsbaum M. S., Ingvar D. H., Kessler R., Waters R. N., Capelletti J., van Kammen D. P., King A. C., Johnson J. L., Manning R. G., Flynn R. W., Mann L. S., Bunney W. E., Sokoloff L. Cerebral glucography with positron tomography. Archives of General Psychiatry 1982; 39: 251–260
   PubMed Web of Science ®Google Scholar
• Buchsbaum M. S., Cappeletti J., Ball R., Hazlett E., King A. C, Johnson J., Wu J., DeLisi L. E. Positron emission tomographic image measurement in schizophrenia and affective disorders. Annals of Neurology, Supplement to Volume 1984; 15: 5157–5165
   Google Scholar
• Costall B., Naylor R. J. Recent developments in the drug treatment of schizophrenia. Biochemistry of schizophrenia and addiction, G. Hemmings. MTP Press, Lancaster 1980; 327–336
   Google Scholar
• Crow T. J. The pathogenesis of schizophrenia. Biochemistry of schizophrenia and addiction, G. Hemmings. MTP Press, Lancaster 1980; 19–38
   Google Scholar
• Daniel P. M., Love E. R., Pratt O. E. The influence of insulin upon the metabolism of glucose by the brain. Proceedings of the Royal Society of London. 1977; 85–104, B196
   Google Scholar
• Donelly J. Discussion in insulin treatment in psychiatry, M. Kinkel, H. E. Himwich. Philosophical Library, New York 1959; 135
   Google Scholar
• Drenick E. J., Alvarez L. C., Tamasi G. C., Brickman A. S. Resistance to symptomatic insulin reactions after fasting. The Journal of Clinical Investigation 1972; 51: 2757–2762
   PubMedGoogle Scholar
• Farkas T., Wolf A. P., Jaeger J., Brodie J. D., Christman D. R., Fowler J. S. Regional brain glucose metabolism in chronic schizophrenia. A positron emission trance-axial tomographic study. Archives of General Psychiatry 1984; 41: 293–300
   PubMed Web of Science ®Google Scholar
• Farkas T., Reivich M., Alavi A., Greenberg J. H., Fowler J. S., MacGregor R. R., Christman D. R., Wolf A. P. The application of (18)2-deoxy-2-fluoro-D-glucose and positron emission tomography in the study of psychiatric conditions. Cerebral metabolism and neural function, J. V. Passonneau, R. A. Hawkins, W. D. Lust, F. A. Welsh. Williams and Wilkins, London 1980; 403–408
   Google Scholar
• Farley L. J., Price R. S., McCullough E., Deck J. H. N., Hordynski W., Hornkykiewicz O. Norepinephrine in chronic paranoid schizophrenia: Above normal levels in limbic forebrain. Science 1978; 200: 456–458
   PubMed Web of Science ®Google Scholar
• Freedman R., Kirch D., Bell J., Adler L. E., Pecevich M., Pachtman E., Denver P. Clonidine treatment of schizophrenia. Acta Psychiatrica Scandanavica 1982; 65: 35–45
   PubMedGoogle Scholar
• Fujimoto A., Nagao T., Ebara T., Sato M., Otsuki S. Cerebrospinal fluid monoamine metabolites during alcohol withdrawal syndrome and recovered state. Biological Psychiatry 1983; 18: 1141–1152
   PubMed Web of Science ®Google Scholar
• Frohman C., Luby E. D., Tourney G., Beckett P. G. S., Gottlieb J. S. Steps toward the isolation of a serum factor in schizophrenia. American Journal of Psychiatry 1960; 117: 401–408
   PubMedGoogle Scholar
• Geiger A. Correlation of brain metabolism and function by the use of a brain perfusion method in situ. Physiological Reviews 1958; 38: 1–20
   PubMedGoogle Scholar
• Gianini A. J., Houser W. L., Jr., Loiselle R. H., Giannini M. C., Price W. A. Antimanic effects of verapamil. American Journal of Psychiatry 1984; 141: 1602–1603
   PubMedGoogle Scholar
• Gluckman L. Ventolin psychosis. New Zealand Medical Journal 1974; 80: 411
   PubMedGoogle Scholar
• Gordon M., Zeller W., Donnelly J. A biochemical evaluation of the activity of certain tranquilizers and their relationship to hormonal function. American Journal of Psychiatry 1957; 114: 201–205
   PubMedGoogle Scholar
• Grahame-Smith D. G., Orr M. W. Clinical psychopharmacology. Recent advances in clinical pharmacology, P. Turner, D. G. Shand. Churchill Livingstone, New York 1978; 175–187
   Google Scholar
• Greaves M. F. Cellular recognition. Chapman and Hall, London 1975; 26–32
   Google Scholar
• Harik S. T., LaManna J. C, Light A. I., Rosenthal M. Cerebral norepinephrine: Influence on cortical oxidative metabolism in situ. Science 1979; 206: 69–71
   PubMed Web of Science ®Google Scholar
• Harden T. K. Agonist-induced desensitization of the beta-adrenergic receptor-linked adenylate cyclase. Pharmacological Reviews 1983; 35: 5–32
   PubMed Web of Science ®Google Scholar
• Havrankova J., Roth J., Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature 1978; 272: 827–829
   PubMed Web of Science ®Google Scholar
• Heffner T. G., Hartman J. A., Seiden L. S. Feeding increases dopamine metabolism in the rat brain. Science 1980; 208: 1169–1170
   Google Scholar
• Henneman D. H., Altschule M. D., Gomez R. M. Carbohydrate metabolism in brain disease. Archives of Internal Medicine 1954; 94: 402–416
   Google Scholar
• Hertz M. M., Paulson O. B., Barry D. I., Christiansen J. S., Svendsen P. A. Increases glucose transfer across the blood-brain barrier in man. Journal of Clinical Investigation 1981; 67: 597–604
   PubMedGoogle Scholar
• Hokfelt T., Rehfeld J. F., Skirboll L., Ivemark B., Goldstein M., Markey K. Evidence for coexistence of dopamine and CCK in meso-limbic neurones. Nature 1980; 285: 476–478
   PubMed Web of Science ®Google Scholar
• Iversen S. D., Fray P. J. Brain catecholamines in relation to affect. The neural basis of behavior, A. L. Beckman. MTP Press, LancesterEngland 1982; 229–269, Chapter 12
   Google Scholar
• Kebabian J. W., Calne D. B. Multiple receptors for dopamine. Nature 1979; 277: 93–96
   PubMed Web of Science ®Google Scholar
• Kessler R. M., Clark C. M., Buchsbaum M. S., Holcom H., Margolin R. A., Cappeletti J., Channing M., Manning R. G., van Kammen D. P., King A. C., Johnson J. Regional correlations in patterns of glucose use in patients with schizophrenia and normal subjects during mild pain stimulation. Positron emission tomography of the brain, W. D. Heiss, M. E. Phelps. Springer-Verlag, New York 1983; 196–200
   Google Scholar
• Kruk Z. L., Pycock C. L. Neurotransmitters and drugs. Croom Helm, London 1979; 48–55
   Google Scholar
• Lake C. R., Sternberg D. E., van Kammen D. P., Ballenger J. C, Ziegler M. G., Post R. M., Kopin I. J., Bunney W. E. Schizophrenia: Elevated cerebrospinal fluid norepinephrine. Science 1980; 207: 331–333
   PubMed Web of Science ®Google Scholar
• Lecrubier Y., Puech A S. J., Jouvent R., Simon P., Widlocher D. A beta-adrenergic stimulant (salbutamol) versus clomipramine in depression: A controlled study. British Journal of Psychiatry 1980; 136: 354–358
   PubMedGoogle Scholar
• Lozovsky D. B., Kopin I. J., Sailer C. F. Chronic insulin treatment modulates dopamine receptor supersensitivity: Implication in schizophrenia. Abstracts. IVth World Congress of Biological Pscyhiatry, PhiladelphiaUSA, September, 8–13, 1985; 81
   Google Scholar
• Lynch H. D., Anderson M. H. Atropine coma therapy in psychiatry: Clinical observations over a 20 year period and a review of the literature. Diseases of the Nervous System 1975; 36: 648–652
   PubMedGoogle Scholar
• Mandel M. R., Severe J. B., Schooler N. R., Gelenberg A. J., Mieske M. Development and prediction of postpsychotic depression in neuroleptic-treated schizophrenics. Archives of General Psychiatry 1982; 39: 197–203
   PubMed Web of Science ®Google Scholar
• Margolis R. U., Altszuler N. Insulin in the cerebrospinal fluid. Nature 1967; 215: 1375–1376
   PubMed Web of Science ®Google Scholar
• Mason S. T., Fibiger H. C. Possible behavioural function for noradrenaline-acetylcholine interaction in brain. Nature 1979; 277: 396–397
   PubMedGoogle Scholar
• McCaleb M. L., Meyers R. D., Singer G., Willis G. Hypothalamic norepinephrine in the rat during feeding and push-pull perfusion with glucose 2-DG, or insulin. American Journal of Physiology 1979; 236: 312–321
   Google Scholar
• Means A. R., Dedman J. R. Calmodulin—an intracellular calcium receptor. Nature 1980; 285: 73–77
   PubMed Web of Science ®Google Scholar
• Moller H. J., Zerssen D. Depressive Symptomatik im statkmaren Behandlungsverlauf von 280 schizophrenen Patienten. Pharmacopsychiatrie 1981; 14: 172–179
   Google Scholar
• Morgan M. Y. Bromocriptine in the treatment of chronic encephalopathy and its effect on the handling of alcohol by control subjects and alcoholics. Research and Clinical Forums 1981; 3: 39–47
   Google Scholar
• Nair N. P. V., Bloom D. M., Nestoros J. N. Cholecystokinin appears to have antipsychotic properties. Progress in Neuropsypharmacology and Biological Psychiatry 1982; 8: 509–512
   Google Scholar
• Nair N. P. V., Bloom D. M., Nestoros J. N., Schwartz G. Therapeutic efficacy of cholecystokinin in neuroleptic schizophrenic subjects. Psychopharmacology Bulletin 1983; 19: 134–136
   Google Scholar
• Patten B. M. Beneficial effect of D-ribose in patient with myadenylate deaminase deficiency. Lancet 1982; 1: 1071
   PubMedGoogle Scholar
• Perkins J. P., Moore M. M. Characterization of the adrenergic receptors mediating a rise in cyclic 3/,5/-adenosine monophosphate in rat cerebral cortex. Journal of Pharmacology and Experimental Therapeutics 1973; 185: 371–378
   PubMedGoogle Scholar
• Puro D. G., Agardh E. Insulin-mediated regulation of neuronal maturation. Science 1984; 225: 1170–1172
   PubMedGoogle Scholar
• Raichle M. E. Positron emission tomography: Progress in brain and brain imaging. Nature 1985; 317: 574–576
   PubMedGoogle Scholar
• Reinis S., Goldman M. The chemistry of behavior. Plenum Press, New York 1982; 125–258
   Google Scholar
• Robbins T. W., Koob G. F. Selective disruption of displacement behaviour by lesions of the mesolimhic dopamine system. Nature 1980; 285: 409–412
   PubMed Web of Science ®Google Scholar
• Rodgers J. E. Roots of madness. Science 1982; 82(3)84–91
   Google Scholar
• Routtenberg A. The reward systems of the brain. Scientific American 1978; 239: 122–131
   Web of Science ®Google Scholar
• Sacks W. Cerebral metabolism of isotopic glucose in chronic mental disease. Journal of Applied Physiology 1959; 14: 849–854
   PubMedGoogle Scholar
• Saito A., Sankaran H., Goldfine I. D., William J. A. Cholecystokinin receptors in the brain: Characterization and distribution. Science 1980; 208: 1155–1156
   PubMed Web of Science ®Google Scholar
• Sandyk R. The effect of dopamine hydrochloride on insulin action in isolated rat adipocytes. M.Sc. Thesis, Department of Pharmacology, University of the Witwatersrand, Johannesburg 1984
   Google Scholar
• Schardt F., Hesse R. The effect of nadolol on lipolysis. International experience with Nadolol—A long-acting beta-blocking agent, F. Gross. No. 37 in International Symposium Series, Royal Society of Medicine, London 1979; 45–50
   Google Scholar
• Schmidt P. Über Organtherapie und Insulinbehandlung bei endogenen Geistesstorungen. Klinik Woch 1928; 7: 839
   Google Scholar
• Wortis J. Insulin Treatment in Psychiatry, M. Rinkel, H. E. Himwich. Philosophical Library, New York, 20
   Google Scholar
• Schneider B. S., Monahan J. W., Hirsch J. Brain cholecystokinin and nutritional status in rats and mice. Journal of Clinical Investigation 1979; 64: 1348–1356
   PubMedGoogle Scholar
• Schultz J. Psychoactive drug effects on a system which generates cyclic AMP in brain. Nature 1976; 261: 417–418
   PubMedGoogle Scholar
• Schwartz W. J., Sharp F. R., Gunn R. F., Evarts E. V. Lesions of ascending dopaminergic pathways decrease forebrain glucose uptake. Nature 1976; 261: 155–157
   PubMedGoogle Scholar
• Sem-Jacohsen C. W., Petersen M. C., Lazarte J. A., Dodge H. W., Holman C. B. lntracerebral electrographic recordings from psychotic patients during hallucinations and agitation. The Amercican Journal of Psychiatry 1955; 112: 278–288
   PubMedGoogle Scholar
• Sem-Jacobsen C. W., Styri O. B. Manipulation of emotion: Electrophysiological and surgical methods. Emotions—their parameters and measurement, M. Levi. Raven Press, New York 1975; 645–676
   Google Scholar
• Sikes J. C., Sikes Z. S. Lithium carbonate treatment in psychiatry. Diseases of the Nervous System 1970; 31: 52–55
   PubMedGoogle Scholar
• Skirboll L. R., Grace A. A., Bunney B. S. Dopamine auto- and poslsynaptic receptors: Electrophysiological evidence for differential sensitivity to dopamine agonists. Science 1979; 206: 80–82
   PubMed Web of Science ®Google Scholar
• Smythe G. A., Grunstein H. S., Bradshaw J. E., Nicholson M. V., Compton P. J. Relationships between brain noradrenergic activity and blood glucose. Nature 1984; 308: 65–67
   PubMed Web of Science ®Google Scholar
• Smythies J. R. Biochemistry of schizophrenia. Postgraduate Medical Journal 1963; 39: 26–33
   PubMedGoogle Scholar
• Sternberg D. E., Charney D. S., Heninger G. R., Leckman J. F., Hafstad K. M., Landis D. H. Impaired presynaptic regulation of norepinephrine in schizophrenia. Archives of General Psychiatry 1982; 39: 285–289
   PubMed Web of Science ®Google Scholar
• Tamminga C. A., Schaffer M. H., Smith R. C., Davis J. M. Schizophrenic symptoms improve with apomorphine. Science 1978; 200: 567–568
   PubMed Web of Science ®Google Scholar
• Tassin J. P., Simon H., Herve D., Blanc G., LeMoal M., Glowinski J., Bockaert J. Non-dopaminergic fibres may regulate dopamine-sensitive adehylate cyclase in the prefrontal cortex and nucleus accumbens. Nature 1982; 295: 696–698
   PubMed Web of Science ®Google Scholar
• Thierry A. M., Tassin J. P., Blanc G., Glowinski J. Selective activation of the mesocortical DA system by stress. Nature 1976; 263: 242–244
   PubMed Web of Science ®Google Scholar
• Tien H. C. Pattern recognition in mental disorders and the organic integrity tests (OIT). Psychosomalics 1969; 10: 29–35
   PubMedGoogle Scholar
• Valverde I., Malaisse W. J. Calmodulin and pancreatic B-cell function. Experientia 1984; 40: 1061–1068
   PubMedGoogle Scholar
• van Houten M., Posner B. I. Insulin binds to brain blood vessels in vivo. Nature 1979; 282: 623–625
   PubMed Web of Science ®Google Scholar
• van Houten M., Posner B. I., Kopriwa B. M., Brawer J. R. Insulin binding sites localised to nerve terminal in rat median eminence and arcuate nucleus. Science 1980; 207: 1081–1083
   PubMedGoogle Scholar
• Widen L., Bergstrom M., Blomgvist C., Bohm C., Ehrin E., Elander S., Ericson K., Eriksson L., Greitz T., Ingvar D. H., Litton J. E., Nilsson L., Sedvall G., Wiesel F. Positron emission tomography studies of brain energy metabolism in schizophrenia. Positron emission tomography of the brain, W. D. Heis, M. E. Phelps. Springer-Verlag, New York 1983a; 192–195
   Google Scholar
• Widen L., Blomqvist G., Greitz T., Litton J. E., Bergstrom M., Ehrin E., Ericson K., Eriksson L., Ingvar D. H., Johansson L., Nilsson J. L. G., Stone-EIander S., Sedvall G., Wiesel F., Wiik G. PET studies of glucose metabolism in patients with schizophrenia. American Journal of Neuroradiology 1983b; 550–552
   PubMedGoogle Scholar
• Widlocher D., Lecrubier Y., Jouvent R., Puech A. J., Simon P. Antidepressant effect of salbutamol. Lancet 1977; 2: 767–768
   PubMedGoogle Scholar
• Woods S. C, Lotter E. C, McKay D., Porte D., Jr. Chronic intracerebroventricular infusion of insulin reduces food intake and body weight of baboons. Nature 1979; 282: 503–505
   PubMed Web of Science ®Google Scholar
• Wortis J., Bowman K. M., Goldfarb W. The use of insulin in the treatment of alcoholism. Medical Clinics of North America 1940; 24: 671–681
   Google Scholar
• Yang J. W., Fellows R. E. Characterization of insulin stimulation of the incorporation of radioactive precursors into macromolecules in cultured rat brain cells. Endocrinology 1980; 107: 1717–1724
   PubMedGoogle Scholar
• Yorkston N. J., Zaki S. A., Weller M. P., Gruzelier J. H., Hirsch S. R. DL-propranolol and chlorpromazine following admission for schizophrenia. Acta Psychiatrica Scandinavica 1981; 63: 13–27
   PubMedGoogle Scholar
• Yorkston N. J., Gruzelier J. H., Zaki S. A. Propranolol in the treatment of schizophrenia. Stress and the heart, interactions of the cardiovascular system, behavioral state, and psychotropic drugs (Second Edition), D. Wheatley. Raven Press, New York 1981; 91–104
   Google Scholar
• Young R. L., Albano R. F., Charnecki A. M., Sheppard H. Alteration of glucose and glycogen in specific regions of the mouse central nervous system of L-3–4, dihydroxyphenylalanine (levodopa). Biochemical Pharmacology 1971; 20: 916–919
   PubMedGoogle Scholar
• Zimmer H. G., Ibel H., Steinkopff G, Korb G. Reduction of the isoproterenol-induced alterations in cardiac adenine nucleotides and morphology by ribose. Science 1980; 207: 319–320
   PubMedGoogle Scholar